	US 12,383,553 B2
	Method for detecting or treating triple negative breast cancer
Debra Auguste, Briarcliff Manor, NY (US); Marsha A. Moses, Brookline, MA (US); and Peng Guo, Natick, MA (US)
Assigned to Children's Medical Center Corporation, Boston, MA (US)
Filed by Children's Medical Center Corporation, Boston, MA (US)
Filed on Dec. 29, 2022, as Appl. No. 18/091,145.
Application 18/091,145 is a continuation of application No. 15/127,240, abandoned, previously published as PCT/US2015/023078, filed on Mar. 27, 2015.
Claims priority of provisional application 61/970,943, filed on Mar. 27, 2014.
Prior Publication US 2023/0248721 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 9/14 (2006.01); A61K 31/191 (2006.01); A61K 31/429 (2006.01); A61K 31/4365 (2006.01); A61K 31/4965 (2006.01); A61K 39/395 (2006.01); A61K 47/54 (2017.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)

CPC A61K 31/4965 (2013.01) [A61K 9/14 (2013.01); A61K 31/191 (2013.01); A61K 31/429 (2013.01); A61K 31/4365 (2013.01); A61K 47/555 (2017.08); C12Q 1/6886 (2013.01); G01N 33/57415 (2013.01); A61K 2121/00 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/70525 (2013.01)]

5 Claims

1. A method of treating triple negative breast cancer (TNBC) in a patient, the method comprising administering enlimomab to the patient, wherein administering the enlimomab reduces TNBC cell migration in the patient.